{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:55:18Z","timestamp":1794851718772,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR056099 and AR065778"],"award-info":[{"award-number":["AR056099 and AR065778"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012462","name":"Department of Veterans Affairs | Office of Academic Affiliations, Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1I01BX002286"],"award-info":[{"award-number":["1I01BX002286"]}],"id":[{"id":"10.13039\/100012462","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Please note that I am the last Author. The first author is Dr. Umar."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41423-020-0433-8","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T11:06:50Z","timestamp":1589540810000},"page":"2199-2210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["IRAK4 inhibition: a promising strategy for treating RA joint inflammation and bone erosion"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4733-5751","authenticated-orcid":false,"given":"Sadiq","family":"Umar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Palasiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Van Raemdonck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Volin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Romay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Asif","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan K.","family":"Zomorrodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Arami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-0221","authenticated-orcid":false,"given":"Nadera","family":"Sweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6698-8491","authenticated-orcid":false,"given":"Shiva","family":"Shahrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"433_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.autrev.2016.12.003","volume":"16","author":"HA Elshabrawy","year":"2017","unstructured":"Elshabrawy, H. A., Essani, A. E., Szekanecz, Z., Fox, D. A. & Shahrara, S. TLRs, future potential therapeutic targets for RA. Autoimmun. Rev. 16, 103\u2013113 (2017).","journal-title":"Autoimmun. Rev."},{"key":"433_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/annrheumdis-2011-201203","volume":"72","author":"ND Chamberlain","year":"2013","unstructured":"Chamberlain, N. D. et al. Ligation of TLR7 by rheumatoid arthritis synovial fluid single strand RNA induces transcription of TNFalpha in monocytes. Ann. Rheum. Dis. 72, 418\u2013426 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"433_CR3","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/art.39544","volume":"68","author":"SJ Kim","year":"2016","unstructured":"Kim, S. J. et al. Identification of a novel toll-like receptor 7 endogenous ligand in rheumatoid arthritis synovial fluid that can provoke arthritic joint inflammation. Arthritis Rheumatol. 68, 1099\u20131110 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"433_CR4","doi-asserted-by":"publisher","first-page":"23653","DOI":"10.1073\/pnas.1915326116","volume":"116","author":"H Negishi","year":"2019","unstructured":"Negishi, H. et al. Identification of U11snRNA as an endogenous agonist of TLR7-mediated immune pathogenesis. Proc. Natl Acad. Sci. USA 116, 23653\u201323661 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"433_CR5","doi-asserted-by":"crossref","unstructured":"Salvi, V., et al. Exosome-delivered microRNAs promote IFN-alpha secretion by human plasmacytoid DCs via TLR7. JCI Insight. 3 (2018).","DOI":"10.1172\/jci.insight.98204"},{"key":"433_CR6","doi-asserted-by":"publisher","first-page":"e48278","DOI":"10.1371\/journal.pone.0048278","volume":"7","author":"Q Li","year":"2012","unstructured":"Li, Q. et al. MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression via down-regulating checkpoint suppressor 1 in human lung cancer. PLoS ONE 7, e48278 (2012).","journal-title":"PLoS ONE"},{"key":"433_CR7","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/ar3875","volume":"14","author":"S Alzabin","year":"2012","unstructured":"Alzabin, S. et al. Investigation of the role of endosomal Toll-like receptors in murine collagen-induced arthritis reveals a potential role for TLR7 in disease maintenance. Arthritis Res Ther. 14, R142 (2012).","journal-title":"Arthritis Res Ther."},{"key":"433_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/gt.2011.173","volume":"19","author":"SY Chen","year":"2012","unstructured":"Chen, S. Y. et al. Suppression of collagen-induced arthritis by intra-articular lentiviral vector-mediated delivery of Toll-like receptor 7 short hairpin RNA gene. Gene Ther. 19, 752\u2013760 (2012).","journal-title":"Gene Ther."},{"key":"433_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fphar.2017.00293","volume":"8","author":"JM Dayer","year":"2017","unstructured":"Dayer, J. M., Oliviero, F. & Punzi, L. A brief history of IL-1 and IL-1 Ra in rheumatology. Front. Pharmacol. 8, 293 (2017).","journal-title":"Front. Pharmacol."},{"key":"433_CR10","doi-asserted-by":"publisher","first-page":"13552","DOI":"10.1074\/jbc.M700548200","volume":"282","author":"M Koziczak-Holbro","year":"2007","unstructured":"Koziczak-Holbro, M. et al. IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and toll-like receptor 7-mediated signaling and gene expression. J. Biol. Chem. 282, 13552\u201313560 (2007).","journal-title":"J. Biol. Chem."},{"key":"433_CR11","doi-asserted-by":"publisher","first-page":"18689","DOI":"10.1074\/jbc.M117.796912","volume":"292","author":"L Cushing","year":"2017","unstructured":"Cushing, L. et al. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes. J. Biol. Chem. 292, 18689\u201318698 (2017).","journal-title":"J. Biol. Chem."},{"key":"433_CR12","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s10753-015-0188-z","volume":"38","author":"W Zhu","year":"2015","unstructured":"Zhu, W. et al. Anti-citrullinated protein antibodies induce macrophage subset disequilibrium in RA patients. Inflammation. 38, 2067\u20132075 (2015).","journal-title":"Inflammation"},{"key":"433_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/ni.1990","volume":"12","author":"T Krausgruber","year":"2011","unstructured":"Krausgruber, T. et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12, 231\u2013238 (2011).","journal-title":"Nat. Immunol."},{"key":"433_CR14","doi-asserted-by":"publisher","first-page":"11001","DOI":"10.1073\/pnas.1506254112","volume":"112","author":"M Weiss","year":"2015","unstructured":"Weiss, M. et al. IRF5 controls both acute and chronic inflammation. Proc. Natl Acad. Sci. USA 112, 11001\u201311006 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"433_CR15","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1002\/art.39321","volume":"67","author":"P Duffau","year":"2015","unstructured":"Duffau, P. et al. Promotion of inflammatory arthritis by interferon regulatory factor 5 in a mouse model. Arthritis Rheumatol. 67, 3146\u20133157 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"433_CR16","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1084\/jem.20061825","volume":"204","author":"TW Kim","year":"2007","unstructured":"Kim, T. W. et al. A critical role for IRAK4 kinase activity in toll-like receptor-mediated innate immunity. J. Exp. Med 204, 1025\u20131036 (2007).","journal-title":"J. Exp. Med"},{"key":"433_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/bs.pmch.2016.11.004","volume":"56","author":"NE Genung","year":"2017","unstructured":"Genung, N. E. & Guckian, K. M. Small molecule inhibition of interleukin-1 receptor-associated kinase 4 (IRAK4). Prog. Med. Chem. 56, 117\u2013163 (2017).","journal-title":"Prog. Med. Chem."},{"key":"433_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1242\/dmm.027409","volume":"10","author":"MG Hasham","year":"2017","unstructured":"Hasham, M. G. et al. Systemic autoimmunity induced by the TLR7\/8 agonist Resiquimod causes myocarditis and dilated cardiomyopathy in a new mouse model of autoimmune heart disease. Dis. Model Mech. 10, 259\u2013270 (2017).","journal-title":"Dis. Model Mech."},{"key":"433_CR19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ni1118","volume":"5","author":"T Kawai","year":"2004","unstructured":"Kawai, T. et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5, 1061\u20131068 (2004).","journal-title":"Nat. Immunol."},{"key":"433_CR20","doi-asserted-by":"publisher","first-page":"e1230578","DOI":"10.1080\/2162402X.2016.1230578","volume":"5","author":"T Spinetti","year":"2016","unstructured":"Spinetti, T. et al. TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function. Oncoimmunology 5, e1230578 (2016).","journal-title":"Oncoimmunology"},{"key":"433_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.02.034","volume":"164","author":"H Kim","year":"2018","unstructured":"Kim, H. et al. Polymeric nanoparticles encapsulating novel TLR7\/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials 164, 38\u201353 (2018).","journal-title":"Biomaterials"},{"key":"433_CR22","doi-asserted-by":"publisher","first-page":"24932","DOI":"10.18632\/oncotarget.15326","volume":"8","author":"JH Cho","year":"2017","unstructured":"Cho, J. H. et al. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma. Oncotarget 8, 24932\u201324948 (2017).","journal-title":"Oncotarget"},{"key":"433_CR23","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.4049\/jimmunol.1600333","volume":"197","author":"Q Xiao","year":"2016","unstructured":"Xiao, Q. et al. TLR7 engagement on dendritic cells enhances autoreactive Th17 responses via activation of ERK. J. Immunol. 197, 3820\u20133830 (2016).","journal-title":"J. Immunol."},{"key":"433_CR24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.4049\/jimmunol.1601890","volume":"199","author":"J Ye","year":"2017","unstructured":"Ye, J. et al. TLR7 signaling regulates Th17 cells and autoimmunity: novel potential for autoimmune therapy. J. Immunol. 199, 941\u2013954 (2017).","journal-title":"J. Immunol."},{"key":"433_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10616-012-9442-5","volume":"64","author":"A Miyamoto","year":"2012","unstructured":"Miyamoto, A. et al. R848, a toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclasts. Cytotechnology 64, 331\u2013339 (2012).","journal-title":"Cytotechnology"},{"key":"433_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1365-2249.2004.02430.x","volume":"136","author":"XJ Ye","year":"2004","unstructured":"Ye, X. J. et al. The roles of interleukin-18 in collagen-induced arthritis in the BB rat. Clin. Exp. Immunol. 136, 440\u2013447 (2004).","journal-title":"Clin. Exp. Immunol."},{"key":"433_CR27","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","volume":"71","author":"S Alzabin","year":"2012","unstructured":"Alzabin, S. et al. Incomplete response of inflammatory arthritis to TNFalpha blockade is associated with the Th17 pathway. Ann. Rheum. Dis. 71, 1741\u20131748 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"433_CR28","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1002\/art.24126","volume":"58","author":"M Fujimoto","year":"2008","unstructured":"Fujimoto, M. et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 58, 3710\u20133719 (2008).","journal-title":"Arthritis Rheum."},{"key":"433_CR29","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1084\/jem.20072707","volume":"205","author":"CA Notley","year":"2008","unstructured":"Notley, C. A. et al. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J. Exp. Med 205, 2491\u20132497 (2008).","journal-title":"J. Exp. Med"},{"key":"433_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/art.38246","volume":"66","author":"A Thiolat","year":"2014","unstructured":"Thiolat, A. et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol. 66, 273\u2013283 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"433_CR31","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1002\/art.34497","volume":"64","author":"F Depis","year":"2012","unstructured":"Depis, F. et al. Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments. Arthritis Rheum. 64, 3189\u20133198 (2012).","journal-title":"Arthritis Rheum."},{"key":"433_CR32","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1172\/JCI26132","volume":"115","author":"H Kitaura","year":"2005","unstructured":"Kitaura, H. et al. M-CSF mediates TNF-induced inflammatory osteolysis. J. Clin. Invest 115, 3418\u20133427 (2005).","journal-title":"J. Clin. Invest"},{"key":"433_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/art.21537","volume":"54","author":"PK Wong","year":"2006","unstructured":"Wong, P. K. et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 54, 158\u2013168 (2006).","journal-title":"Arthritis Rheum."},{"key":"433_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3109\/08916934.2013.798651","volume":"46","author":"FG Zhu","year":"2013","unstructured":"Zhu, F. G. et al. A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW\/F1 mice. Autoimmunity 46, 419\u2013428 (2013).","journal-title":"Autoimmunity"},{"key":"433_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clim.2016.09.015","volume":"174","author":"DM Balak","year":"2017","unstructured":"Balak, D. M. et al. IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. Clin. Immunol. 174, 63\u201372 (2017).","journal-title":"Clin. Immunol."},{"key":"433_CR36","doi-asserted-by":"publisher","first-page":"e84634","DOI":"10.1371\/journal.pone.0084634","volume":"8","author":"M Suarez-Farinas","year":"2013","unstructured":"Suarez-Farinas, M. et al. Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation. PLoS ONE 8, e84634 (2013).","journal-title":"PLoS ONE"},{"key":"433_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41375-019-0507-8","volume":"34","author":"N Gimenez","year":"2020","unstructured":"Gimenez, N. et al. Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. Leukemia 34, 100\u2013114 (2020).","journal-title":"Leukemia"},{"key":"433_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett, F. C. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315\u2013324 (1988).","journal-title":"Arthritis Rheum."},{"key":"433_CR39","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.4049\/jimmunol.1201675","volume":"190","author":"Z Chen","year":"2013","unstructured":"Chen, Z. et al. The novel role of IL-7 ligation to IL-7 receptor in myeloid cells of rheumatoid arthritis and collagen-induced arthritis. J. Immunol. 190, 5256\u20135266 (2013).","journal-title":"J. Immunol."},{"key":"433_CR40","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1136\/annrheumdis-2013-204530","volume":"74","author":"Z Chen","year":"2015","unstructured":"Chen, Z. et al. Characterising the expression and function of CCL28 and its corresponding receptor, CCR10, in RA pathogenesis. Ann. Rheum. Dis. 74, 1898\u20131906 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"433_CR41","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.4049\/jimmunol.1302998","volume":"193","author":"SJ Kim","year":"2014","unstructured":"Kim, S. J. et al. Ligation of TLR5 promotes myeloid cell infiltration and differentiation into mature osteoclasts in rheumatoid arthritis and experimental arthritis. J. Immunol. 193, 3902\u20133913 (2014).","journal-title":"J. Immunol."},{"key":"433_CR42","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/annrheumdis-2016-209206","volume":"76","author":"SJ Kim","year":"2017","unstructured":"Kim, S. J. et al. Differential impact of obesity on the pathogenesis of RA or preclinical models is contingent on the disease status. Ann. Rheum. Dis. 76, 731\u2013739 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"433_CR43","doi-asserted-by":"publisher","unstructured":"Kim, S. J., et al. Macrophages are the primary effector cells in IL-7-induced arthritis. Cell Mol Immunol. https:\/\/doi.org\/10.1038\/s41423-019-0235-z (2019).","DOI":"10.1038\/s41423-019-0235-z"},{"key":"433_CR44","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00018-019-03235-w","volume":"77","author":"K Van Raemdonck","year":"2020","unstructured":"Van Raemdonck, K., et al. CCL21\/CCR7 signaling in macrophages promotes joint inflammation and Th17-mediated osteoclast formation in rheumatoid arthritis. Cell Mol Life Sci. 77, 1387\u20131399 (2020).","journal-title":"Cell Mol Life Sci."},{"key":"433_CR45","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/art.30232","volume":"63","author":"SR Pickens","year":"2011","unstructured":"Pickens, S. R. et al. Characterization of CCL19 and CCL21 in rheumatoid arthritis. Arthritis Rheum. 63, 914\u2013922 (2011).","journal-title":"Arthritis Rheum."},{"key":"433_CR46","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/art.30493","volume":"63","author":"SR Pickens","year":"2011","unstructured":"Pickens, S. R. et al. Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 63, 2884\u20132893 (2011).","journal-title":"Arthritis Rheum."},{"key":"433_CR47","doi-asserted-by":"publisher","first-page":"475","DOI":"10.4049\/jimmunol.1102977","volume":"189","author":"ND Chamberlain","year":"2012","unstructured":"Chamberlain, N. D. et al. TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-alpha levels. J. Immunol. 189, 475\u2013483 (2012).","journal-title":"J. Immunol."},{"key":"433_CR48","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10456-017-9589-y","volume":"21","author":"HA Elshabrawy","year":"2018","unstructured":"Elshabrawy, H. A. et al. IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells. Angiogenesis 21, 215\u2013228 (2018).","journal-title":"Angiogenesis"},{"key":"433_CR49","doi-asserted-by":"publisher","first-page":"5521","DOI":"10.1021\/acs.jmedchem.7b00231","volume":"60","author":"KL Lee","year":"2017","unstructured":"Lee, K. L. et al. Discovery of clinical candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoli ne-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design. J. Med. Chem. 60, 5521\u20135542 (2017).","journal-title":"J. Med. Chem."},{"key":"433_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13075-019-2008-6","volume":"21","author":"SI Danto","year":"2019","unstructured":"Danto, S. I. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects. Arthritis Res Ther. 21, 269 (2019).","journal-title":"Arthritis Res Ther."},{"key":"433_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/art.38878","volume":"67","author":"R Morgan","year":"2015","unstructured":"Morgan, R. et al. Expression and function of aminopeptidase N\/CD13 produced by fibroblast-like synoviocytes in rheumatoid arthritis: role of CD13 in chemotaxis of cytokine-activated T cells independent of enzymatic activity. Arthritis Rheumatol. 67, 74\u201385 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"433_CR52","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/art.30324","volume":"63","author":"SR Pickens","year":"2011","unstructured":"Pickens, S. R. et al. Local expression of interleukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum. 63, 2289\u20132298 (2011).","journal-title":"Arthritis Rheum."},{"key":"433_CR53","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/art.37992","volume":"65","author":"SJ Kim","year":"2013","unstructured":"Kim, S. J. et al. Angiogenesis in rheumatoid arthritis is fostered directly by toll-like receptor 5 ligation and indirectly through interleukin-17 induction. Arthritis Rheum. 65, 2024\u20132036 (2013).","journal-title":"Arthritis Rheum."},{"key":"433_CR54","doi-asserted-by":"publisher","first-page":"10865","DOI":"10.1074\/jbc.M113.544809","volume":"289","author":"L Cushing","year":"2014","unstructured":"Cushing, L. et al. Interleukin 1\/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. J. Biol. Chem. 289, 10865\u201310875 (2014).","journal-title":"J. Biol. Chem."}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0433-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0433-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0433-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:38:39Z","timestamp":1696120719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-0433-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1038\/s41423-020-0433-8","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"assertion":[{"value":"13 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest. VR is employed by Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}